BIO
Dedicated to meeting your evolving oncolytic virus needs
At the forefront of cancer treatment, oncolytic viruses (OVs) have the potential to improve patient health and mortality dramatically.
As a leading OV manufacturing and development expert, ReciBioPharm advances your therapy with the specialised infrastructure and in-depth expertise needed to successfully deliver OVs to the clinic and beyond.
Leading experts in oncolytic virus manufacturing and development
OVs are used in revolutionary therapies that utilise viruses to selectively infect and replicate in tumour tissues, driving an immune response and cell death. These cutting-edge therapies are providing wider treatment options and new hope to cancer patients.
However, OV production is inherently complex, as the virus platforms used are very heterogeneous. As leaders in the OV space, we’re equipped to help you navigate these complexities with confidence.
Comprehensive services backed by expertise
Using our industry-leading viral expertise, ReciBioPharm supports the advancement of your replication-competent or -defective, engineered and wild-type OV innovations through clinical trial phases through to commercialisation.
We provide comprehensive services ranging from analytical/process development to GMP drug substance and drug product manufacturing, including aseptic processing and validation capabilities.
Providing extensive knowledge from experience
Our team of experts has a strong track record of working with a variety of production cell lines, with the capabilities to develop both cell-based (adherent and suspension) and egg-based OV products.
Our oncolytic virus experience
- Arenavirus
- Adenovirus (Ad)
- Herpes simplex (HSV)
- Fowlpox (FPV)
- Modified vaccinia Ankara (MVA)
- Newcastle disease (NDV)
- Measles (MV)
- Vaccinia/modified vaccinia Ankara (MVA)
- Vesicular stomatitis (VSV)
- Egg-based, chick embryo fibroblasts (CEF), and continuous cell lines (including HEK293/T, A549, VERO and MRC-5)
Want to know more about our OV offering?